Find out how to tackle one of the biggest challenges in treating cancer with Genomic testing for cancer treatment Read more
Operations for EndoPredict® and Prolaris® Kits will continue to be based in Cologne, with dedicated teams in sales, marketing, medical and market access support, production, customer support, quality, and regulatory affairs transferring from Myriad Genetics. This ensures that patients will continue to benefit from the same reliable test results, while healthcare providers receive the support they have always relied on.
Eurobio Scientific is committed to enhancing patients’ quality of life through innovative diagnostics. Our vision is to become a global leader in specialty diagnostics, offering cutting-edge solutions to healthcare professionals. With over 370 employees worldwide, we provide robust local support through our manufacturing and research centers, as well as offices in Europe, the USA, and a network of trusted distributors globally. Our expert R&D team focuses on developing advanced molecular diagnostic tests in oncology, transplant, and infectious diseases.
EndoPredict® is a second generation genomic test for breast cancer that provides a thorough analysis of tumor biology. It helps predict the likelihood of cancer recurrence and chemotherapy benefit to support more informed decisions about adjuvant chemotherapy for patients with ER+, HER2- early-stage breast cancer. With its high prognostic accuracy, EndoPredict® enables personalized treatment planning, ensuring that patients receive the most appropriate care based on their individual risk profile.
Prolaris® is a prognostic test for prostate cancer that measures the expression levels of genes involved in cell cycle progression. It provides an accurate assessment of the aggressiveness of prostate cancer, helping to distinguish between indolent and aggressive disease. Prolaris® aids in risk stratification and guides treatment decisions, allowing clinicians to tailor their approach to each patient’s specific cancer biology and risk of progression.
Nothing will change from a product and service standpoint. Our commitment to excellence remains our priority, and you will continue to receive the same high-quality diagnostics and support you have come to rely on; designed, manufactured, and supported by the same team as has done this in the past. This acquisition is not just a change in ownership but a turning point towards a brighter, more innovative future.
There will be no changes in the quality and features of the products.
Myriad has made this strategic move to better serve kit customers with a strong partner in Europe. Through this partnership, we hope to develop EndoPredict® into the leading gene expression test in breast cancer, as well as Prolaris® in prostate cancer.
Your ordering procedures for EndoPredict® and Prolaris® are expected to remain the same. While we do not control the pathology laboratories that perform the tests, we expect that EndoPredict® and Prolaris will® continue to be performed by the same laboratories.
No, there are no expected changes in pricing due to the transition.
The sales team will remain mostly unchanged, so your points of contact for sales inquiries will continue to be the same familiar faces you have worked with so far. This consistency ensures that you will receive the same level of service and support you are accustomed to.
The medical team will remain your point of contact for medical questions, ensuring continuity in the service you are accustomed to. There will be a new email address for inquiries: France: info-FR@eurobio-scientific.de Germany: info-DE@eurobio-scientific.de Austria: info-AT@eurobio-scientific.de Switzerland: info-CH@eurobio-scientific.de Other regions: info-INT@eurobio-scientific.de
Emails sent to the previous address will be automatically forwarded to the new one to ensure a smooth transition period.
All accounts, contracts, and warranties will be seamlessly transferred to the new entity managing the business, with no changes to their terms or conditions.
There will be no changes to the ordering processes and customers do not need to change the ‘supplier’ information or ordering process right now until further notice. The same order numbers, forms, and procedures will remain in place. There will be new ordering email addresses:
France: orders-FR@eurobio-scientific.de Germany: orders-DE@eurobio-scientific.de Austria: orders-AT@eurobio-scientific.de Switzerland: orders-CH@eurobio-scientific.de Other regions: orders-INT@eurobio-scientific.de
Emails sent to the former ordering addresses will be forwarded automatically to the new one for a transitional period.
There are no expected changes in pricing and billing processes. All current pricing structures will remain the same, and the billing procedures you are accustomed to will continue as usual until we advise you of changes.
The support team will remain your point of contact, ensuring continuity in service as you are used to. There will be a new support email address:
kitsupport@eurobio-scientific.de
Emails sent to the former support addresses will be forwarded automatically to the new one to ensure a smooth transition period.
This transition is a crucial step towards advancing innovation and focusing on service quality. Our goal is to ultimately benefit breast and prostate cancer patient care and outcomes, ensuring that more patients receive the advanced diagnostics they need.
We look forward to this new chapter and to serve you and your patients with the highest level of dedication and expertise. If you have any questions, please don’t hesitate to contact us at
info-INT@eurobio-scientific.de
For more exciting updates follow us on LinkedIn!